SANGAMO THERAPEUTICS, INC

SANGAMO THERAPEUTICS, INC is a genomic medicine company developing zinc finger-based epigenetic regulators, engineered AAV capsids and modular integrase technologies to create therapies for serious neurological and other genetic diseases. It offers epigenetic regulation therapies (ZFRs/ZFAs), gene therapy candidates, compact base editors, the MINT integration platform and proprietary AAV capsid variants (e.g., STAC-BBB) for CNS delivery. The business comprises wholly owned preclinical and clinical programs, technology platforms and collaborations/licenses with biopharma partners. It pursues global clinical development and distribution using intravenous, intrathecal and cerebrospinal fluid delivery routes and partner-led commercialization.

Summary from filing dated 2025-03-17